The aim of the present study was to identify the signaling mechanisms to ghrelin-stimulated activation of the serine/threonine kinase Akt. In human embryonic kidney 293 (HEK293) cells transfected with GHS-R1a, ghrelin leads to the activation of Akt through the interplay of distinct signaling mechanisms: an early Gi/o protein-dependent pathway and a late pathway mediated by β-arrestins. The starting point is the Gi/o-protein dependent PI3K activation that leads to the membrane recruitment of Akt, which is phosphorylated at Y by c-Src with the subsequent phosphorylation at A-loop (T308) and HM (S473) by PDK1 and mTORC2, respectively. Once the receptor is activated, a second signaling pathway is mediated by β-arrestins 1 and 2, involving the recruitment of at least β-arrestins, c-Src and Akt. This β-arrestin-scaffolded complex leads to full activation of Akt through PDK1 and mTORC2, which are not associated to the complex. In agreement with these results, assays performed in 3T3-L1 preadipocyte cells indicate that β-arrestins and c-Src are implicated in the activation of Akt in response to ghrelin through the GHS-R1a. In summary this work reveals that c-Src is crucially involved in the ghrelin-mediated Akt activation. Furthermore, the results support the view that β-arrestins act as both scaffolding proteins and signal transducers on Akt activation.
Citation: Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF, Camiña JP (2009) c-Src Regulates Akt Signaling in Response to Ghrelin via β-Arrestin Signaling-Independent and -Dependent Mechanisms. PLoS ONE 4(3): e4686. doi:10.1371/journal.pone.0004686
Editor: Dong-Yan Jin, University of Hong Kong, Hong Kong
Received: September 18, 2008; Accepted: January 22, 2009; Published: March 5, 2009
Copyright: © 2009 Lodeiro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion: PI060239, PI060705, PI070908), and Xunta de Galicia (PGIDIT05BTF20802PR, PGIDIT06PXIB918322PR, PGIDIT06PXIB918360PR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work of M Lodeiro is funded by Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion). The work of M Theodoropoulou was supported by a research fellowship at the University of Santiago de Compostela for the Pfizer Young Investigator Fellowship. The work of JP Camina is funded by the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion) and the Xunta de Galicia (SERGAS) through a research-staff stabilization contract.
Competing interests: The authors have declared that no competing interests exist.
The growth hormone secretagogue receptor type 1a (GHS-R1a1) transduces the main signals carried by ghrelin participating in the regulation of growth hormone release, food intake and energy homeostasis . Ghrelin stimulation of GHS-R1a results in activation of heterotrimeric G proteins followed by receptor phosphorylation that leads to the β-arrestin recruitment, which then sterically interdicts further coupling to G proteins and targets the receptor for internalization , . The ghrelin/GHS-R1a complex is internalized by a clathrin-mediated mechanism through an endosomal trafficking pathway. Once the ligand-receptor complex is internalized into vesicles, GHS-R1a is sorted into endosomes to be slowly recycled back to the plasma membrane . This slow recycling might be determined by the stability of the complex GHS-R1a/β-arrestin during clathrin-mediated endocytosis since this complex appears to dictate the profile of the receptor resensitization . Indeed, ghrelin-stimulated GHS-R1a shows significant endosomal β-arrestin recruitment . In addition to the role of β-arrestin in terminating G protein signaling, recent studies have demonstrated that β-arrestins also function as scaffold molecules for numerous signaling networks such as protein kinases, including the mitogen activated protein kinases, extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal Kinase (JNK), and p38 mitogen-activated protein kinase (p38), as well as Akt, PI3K and RhoA .
The signaling mechanisms that underlie the activation of the mitogenic ERK growth response by the GHS-R1a are complex and result from both classical G protein-regulated effectors and β-arrestin dependent ERK recruitment . One pathway is Gi/o-dependent and it is mediated by phosphatidylinositol 3-kinase (PI3K), protein kinase Cε (PKCε) and non-receptor tyrosine kinase c-Src (c-Src). The second pathway is Gq/11-dependent and involves the activation of protein kinase Cα/β (PKCα/β) and c-Src. A third pathway involves the recruitment of GHS-R1a, c-Src, Raf-1 and ERK 1/2 into a β-arrestin-scaffolded complex. G protein and β-arrestin mediated ERK pathways are both temporally different and act in a sequential way. The β-arrestin-scaffolded signaling complex persists for prolonged periods and it is probably determined by the stability of the β-arrestin /ghrelin receptor complexes. It has become increasingly recognized that these scaffolding complexes can determine the subcellular location and specificity, promoting phosphorylation of diverse cytosolic substrates and thereby having different physiological consequences .
The GHS-R1a has been implicated in Akt signaling, a serine/threonine kinase that exerts a central role in the regulation of metabolism, apoptosis, transcription and cell-cycle . Although previous studies have shown the activation of Akt in endothelial –, skeletal muscle , thyroid , preadipocytes  and pancreatic cells , the molecular events that follow GHS-R1a ligand binding to trigger Akt activation remain unknown. To better understand these molecular mechanisms, we used HEK 293 cells stably expressing the GHS-R1a (HEK-GHSR1a) and 3T3-L1 preadipocyte cells. The experiments were designed to assess the roles, if any, played by G proteins and β-arrestins.
Human ghrelin was obtained from Global Peptide (CO, USA). Pertussis toxin was from Sigma (St. Louis, Mo, USA). Wortmannin, PP2 and PP3 were purchased from Calbiochem (San Diego, CA, USA). Anti-p44/42 MAPK rabbit polyclonal, anti-pSrc (Y416) rabbit polyclonal, anti-pAkt HM (S473), anti-pAkt A-loop (T308), anti-Akt rabbit polyclonal, anti-Rictor rabbit polyclonal, anti-mTOR rabbit polyclonal and anti-pPDK1 (S241) rabbit polyclonal antibodies were from Cell Signaling Technology (Beverly, MA, USA). Rictor siRNA and siRNA control were synthesized by Cell Signaling Technology (Beverly, MA, USA). Anti-pY rabbit polyclonal antibody was from Upstate Technology (Lake Placed, NY, USA). Anti-β-arrestin 1 goat polyclonal, anti-β-arrestin 2 mouse monoclonal and anti-c-Src rabbit polyclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). β-arrestin 1 siRNA, β-arrestin 2 siRNA, c-Src siRNA and siRNA control were likewise from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-rabbit horseradish peroxidase was from GE-Amersham, (Buckinghamshire, UK), while anti-goat horseradish peroxidase was from Santa Cruz (Santa Cruz, CA, USA). Rabbit anti-rat β-arrestin 1C-terminal (A1CT) antiserum was provided by Prof. R.J. Lefkowitz (Duke University Medical Center, Durham, NC, USA).
HEK 293 cells, which stably express the human ghrelin receptor 1a (HEK-GHSR1a), were cultured as previously described . 3T3-L1 preadipocyte cells were obtained from American Type Culture Collection and maintained in DMEM containing 10% calf serum, 100 U/ml penicillin, and 100 U/ml streptomycin. Cells were grown under a humidified atmosphere of 95% air, and 5% CO2 at 37°C.
Cell transient transfection
The cDNA encoding Gβγ sequester β-ARK-CT (gift of P. Voigt, Institute of Pharmacology, Charité-Medical Universiy, Campus Benjamin Franklin, Berlin, Germany) was transfected into subconfluent HEK-GHSR1a cells using Lipofectamine 2000 (Invitrogen; Carlsbad, CA, USA) following the manufacture's protocol. The β-ARK-CT incorporation was confirmed by means of intracellular calcium measurements in transfected cells before and after treatment as previously described .
Serum-starved cells were stimulated with ghrelin for the indicated time period at 37°C. The media was then aspirated and the cells were lysed in ice-cold RIPA buffer [Tris-HCl (pH 7.2), 50 mM; NaCl, 150 mM; EDTA, 1 mM; NP-40, 1% (v/v); Na-deoxycholate, 0.25% (w/v); protease inhibitor cocktail (Sigma; St. Louis, Mo, USA); phosphatase inhibitor cocktail (Sigma; St. Louis, Mo, USA)]. The solubilized lysates were transferred into centrifuge tubes and left at 4°C for 15 min, then pre-cleared by centrifuging at 13,000×g for 15 min. Protein concentration was evaluated with the QuantiPro™ BCA assay kit (Sigma; St. Louis, Mo, USA). Subsamples (same amount of protein) of each sample were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were incubated with 5% non-fat dry milk in TBST [Tris-HCl (pH 8.0), 20 mM; NaCl, 150 mM; Tween-20, 0.1% (v/v); used for all incubation and washing steps] for 1 h. Next, blots were incubated for 1 h with the corresponding antibodies according to the manufacturer's instructions. The blots were subsequently incubated with the corresponding peroxidase-conjugated IgG antibody. After washing, signals were visualized using an enhanced chemiluminescence detection system (GE-Amersham; Buckinghamshire, UK).
Serum-starved cells were stimulated with ghrelin for the indicated time period at 37°C and lysed in ice-cold non-denaturing NP-40 solubilization buffer [immunoprecipitation lysis buffer (ILB), Tris-HCl (pH 7.5), 20 mM; NaCl, 150 mM; EDTA, 1 mM; NP-40, 1% (v/v); protease inhibitor cocktail (Sigma, St. Louis, Mo, USA); phosphatase inhibitor cocktail (Sigma; St. Louis, Mo, USA)]. 500 µg of total protein was pre-washed with 20 µL of 50% protein A/G-agarose (Santa Cruz; Santa Cruz, CA, USA) for 30 min at 4°C, and then incubated with 1 µg of the corresponding antibody (overnight at 4°C) followed by addition of 40 µL of 50% protein A/G (2 h at 4°C). After washing two times with ILB, the pelleted beads were resuspended in Laemmli sample buffer. Proteins were analyzed by 10% SDS-polyacrylamide gels, followed by Western blotting.
Small Interfering RNA (siRNA) Silencing of Gene Expression
Chemically synthesized double-stranded siRNA duplexes (with 3′ dTdT overhangs) were purchased from Santa Cruz Biothecnology for the following targets: β-arrestin 1 (5′-AAAGCCUUCUGCGCGGAGAAU-3′), β-arrestin 2 (5′-AAGGACCGCAAAGUGUUUGUG-3′, 5′-AAAGCCUUCUGCGCGGAGAAU-3′, 5′-AAGGACCGCAAAGUGUUUGUG-3′), Rictor (5′-CACUUCGAUUAGUCAGAAA-3′, 5′-CGCUUACUUUGCCUAACAA-3′, 5′-CCAACUGAGUGCAAUAUGU-3′), c-Src (5′-CUCGGCUCAUUGAAGACA-3′, 5′-UGACUGAGCUCACCACAAA-3′, 5′-CCUCAUCAUAGCAAUAACA-3′, 5′-GUAGAUUUCAGAUGACUAU-3′). A non-silencing RNA duplex was used as a control for all siRNA experiments. Cells were transfected with Lipofectamine 2000 (Invitrogen; Carlsbad, CA, USA), according to manufacturers' instructions. Silencing was quantified by immunoblotting. Only experiments with verified silencing were used.
Akt temporal pattern activation by ghrelin
Figure 1A shows that Akt phosphorylation in both the activation loop within the kinase domain [A-loop (T308)] and the hydrophobic motif in the C-terminal region [HM (S473)] reached maximal levels within 20 min of ghrelin stimulation (100 nM), keeping the maximum by 60 min. The role of Gi/o protein was evaluated by means of pretreatment with pertussis toxin, which uncouples Gi/o protein from receptors (PTX; 100 ng/mL, 12 h). As shown in Figure 1B, PTX reduced the ghrelin-induced phosphorylation of the Akt A-loop (T308). Surprisingly, PTX pretreatment showed an increase of Akt HM (S473) phosphorylation after ghrelin stimulation. Transfection with Gβγ sequesters, β-ARK-CT, decreased the effect of ghrelin on Akt phosphorylation at both residues, indicating the involvement of the βγ-subunit of G proteins (Fig. 1B). Pretreatment with the PI3K inhibitor wortmannin (1 µM, 30 min) decreased the ghrelin-induced Akt phosphorylation at both residues (Fig. 1B).
A, Time-course of the effect of ghrelin on Akt HM (S473) and A-loop (T308) phosphorylation. B, Ghrelin-induced Akt phosphorylation in the absence or presence of PTX (100 ng/mL, 12 h), PI3K inhibitor wortmannin (1 µM, 30 min) and βγ sequester β-ARK-CT. In A and B, serum-starved HEK-GHSR1a cells were treated with ghrelin (100 nM) at 37°C for the indicated times. Cells were lysed and analyzed by SDS-PAGE using specific antibodies. Akt phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation obtained for each residue (mean±S.E. of three independent experiments). Blots are representative of three independent experiments.
c-Src tyrosine kinase regulates Akt activity
Akt phosphorylation was strongly inhibited at both residues by the selective Src inhibitor PP2 (5 µM, 30 min) for all time tested. This inhibition was specific, since pretreatment with PP3 (5 µM, 30 min), a negative control for PP2, had no effect on the ghrelin-induced Akt phosphorylation (data not shown). As shown in Figure 2A, siRNA experiments targeting c-Src reduced its expression by 57±2% (Fig. 2A). In the presence of a non-targeting control siRNA, ghrelin-activated Akt phosphorylation was identical to that observed without any transfection. c-Src siRNA decreased ghrelin-activated Akt phosphorylation with respect to siRNA control for all time tested [54±3% at HM(S473); and, 45±6% at A-loop(T308)]. Immunoprecipitation assays of Akt showed an increase of Y phosphorylation of this kinase in ghrelin-treated cells (100 nM, 5 min) in comparison with untreated cells (Fig. 2B). Furthermore, the activated form of c-Src, pSrc (Y416), co-immunoprecipitated with Akt, which demonstrates a direct interaction between both kinases. Immunoprecipitation assays of Akt in the presence of c-Src siRNA (66±2% reduction in c-Src expression) clearly decreased Y phosphorylation of this kinase in ghrelin-treated cells (100 nM, 5 min) in comparison with non-targeting control siRNA cells (Fig. 2C). c-Src siRNA decreased ghrelin-activated Akt phosphorylation and coimmunoprecipitation of pSrc (Y416) with respect to siRNA control.
A, Effect of siRNA depletion of c-Src on ghrelin-induced Akt phosphorylation. HEK-GHSR1a cells transfected with c-Src siRNA were serum-starved for 12 h and then stimulated with ghrelin (100 nM) at 37°C. After stimulation, equal amounts of protein in each sample were used to assess the expression of c-Src (left panel) and Akt phosphorylation (right panel) by western blotting. Expression of c-Src was quantified by densitometry and expressed as percentages of the level of c-Src in control siRNA-transfected cells (mean±S.E.). Akt phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation at HM (S473) and A-loop (T308) after ghrelin addition to control siRNA-transfected cells (mean±S.E.). B, Effect of ghrelin on Y phosphorylation of Akt and interaction between Akt and c-Src. Cells were incubated with ghrelin (100 nM, 5 min) at 37°C, lysed and immunoprecipitated (IP) with antibodies to Akt, and then analyzed by western blotting with pAkt HM(S473), pY, pSrc (Y416) antibodies. C, Effect of ghrelin on Y phosphorylation of Akt in the presence of c-Src siRNA. HEK-GHSR1a cells transfected with c-Src siRNA were serum-starved for 12 h and then stimulated with ghrelin (100 nM, 5 min) at 37°C. Equal amounts of protein in each sample were used to assess the expression of c-Src [upper panel; values shown (mean±S.E.) are percentages of the level of c-Src in control siRNA-transfected cells]. Cells were lysed and immunoprecipitated (IP) with antibodies to Akt, and then analyzed by western blotting with with pAkt HM(S473), pY, pSrc (Y416) antibodies. Immunoblots are representative of three independent experiments.
3-phosphoinositide-dependent protein kinase 1 (PDK1) and mammalian rapamycin-insensitive complex 2 (mTORC2) mediate Akt phosphorylation activated by ghrelin
Figure 3A shows that pPDK1 (S241) reached maximal levels within 5–10 min of ghrelin stimulation (100 nM), decreasing to ∼50% of the maximum by 60 min after stimulation. This increase was parallel to the phosphorylation of Akt A-loop (T308). Pretreatment of cells with PTX (100 ng/mL, 12 h) had a significant inhibitory effect on ghrelin-induced pPDK1 (S241) (100 nM, 5 min). Inhibition of PI3K by wortmannin pretreatment (1 µM, 30 min) inhibited the ghrelin-induced pPDK1 (S241) (Fig. 3B). On the other hand, working in the presence of Rictor siRNA (50±2% reduction in Rictor expression; Fig. 3C), Akt HM (S473) phosphorylation was reduced by 50±4%, whereas A-loop (T308) phosphorylation was not affected (Fig. 3C).
A, Time-course of the effect of ghrelin (100 nM) on phosphorylation of PDK1. Cell extracts were analyzed by SDS-PAGE using specific antibody against pPDK1 (S241) and Akt. PDK1 phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation (mean±S.E of three independent experiments). B, PDK1 phosphorylation induced by ghrelin (100 nM, 5 min) in the absence or presence of PTX (100 ng/mL, 12 h) and the PI3K inhibitor wortmannin (1 µM, 30 min). PDK1 phosphorylation was quantified by densitometry and expressed as the percentage of the basal phosphorylation obtained in control cells (means±S.E.). C, Effects of siRNA depletion of Rictor on ghrelin-induced Akt phosphorylation. HEK-GHSR1a cells transfected with Rictor siRNA were stimulated with ghrelin (100 nM) at 37°C. After stimulation, cell extracts were prepared as described in Experimental Procedures. Equal amounts of protein in each sample were used to assess the expression of Rictor and Akt phosphorylation by Western blotting. Expression of Rictor was quantified by densitometry. Shown values are percentages of the level of Rictor in control siRNA-transfected cells. Akt phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation of Akt HM (S473) and A-loop (T308) after ghrelin stimulation to control siRNA-transfected cells (mean±S.E.). In A, B and C, blots are representative of three independent experiments.
Regulation of Akt phosphorylation by β-arrestins
siRNA experiments targeting β-arrestin 1 or β-arrestin 2 reduced their expression by 45±2% and 55±4%, respectively (Fig. 4A). In the presence of a non-targeting control siRNA, ghrelin-activated Akt phosphorylation was identical to that observed without any transfection (data not shown). β-arrestin 1 and β-arrestin 2 siRNA led to rapid Akt phosphorylation, which decreased after 10 min of ghrelin stimulation with respect to siRNA control [41±2% and 39±3% at HM(S473) for β-arrestin 1 and β-arrestin 2 siRNA, respectively; and, 47±5% and 40±4% at A-loop(T308), for β-arrestin 1 and β-arrestin 2 siRNA, respectively (Fig. 4A)]. This inhibitory effect stayed on both residues for at least 60 min. Immunoprecipitation of ghrelin-treated cells (100 nM, 10 min) with antibodies for β-arrestin 1 or β-arrestin 2 coprecipitated pAkt (T308, S473), while failed to coprecipitate pPDK1 (S241), Rictor and mTOR (Fig. 4B). The β-arrestin-dependent Akt phosphorylation was dependent on Src as no immunoprecipitation of pAkt was obtained with antibodies to β-arrestin 1 or β-arrestin 2 in ghrelin stimulated cells (100 nM, 10 min) after pretreatment with PP2 (5 µM, 30 min). This inhibition was specific, since pretreatment with PP3 (5 µM, 30 min) had no effect on the β-arrestin-dependent Akt phosphorylation induced by the agonist (data not shown).
A, Effect of siRNA depletion of β-arrestin 1 or β-arrestin 2 on ghrelin-induced Akt phosphorylation. HEK-GHSR1a cells transfected with β-arrestin 1 or β-arrestin 2 siRNA were serum-starved for 12 h and then stimulated with ghrelin (100 nM) at 37°C. After stimulation, equal amounts of protein in each sample were used to assess the expression of β-arrestin 1 or β-arrestin 2 (upper panel) and Akt phosphorylation (lower panel) by Western blotting. Expression of β-arrestin 1 or β-arrestin 2 was quantified by densitometry. Values shown are percentages of the level of β-arrestins in control siRNA-transfected cells. Akt phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation at HM (S473) and A-loop (T308) after ghrelin addition to control siRNA-transfected cells (mean±S.E.). B, Effect of ghrelin on the assembly of complexes containing β-arrestins 1 and 2 and pAkt. Cells were incubated with ghrelin (100 nM, 10 min) at 37°C, lysed and immunoprecipitated (IP) with antibodies to β-arrestin 1 (left panel) or β-arrestin 2 (right panel), and then analyzed by western blotting with pAkt[HM(S473), A-loop(T308), pPDK1 (S241)], Rictor, mTOR, and β-arrestin (A1CT) antibodies. In A and B, western blots are representative of three independent experiments.
Regulation of Akt phosphorylation by Src and β-arrestins in 3T3-L1 preadipocyte cells
As shown in Figure 5A, both Akt A-loop (T308) and HM (S473) phosphorylation reached maximal levels within 20–60 min of ghrelin addition (100 nM). The Akt phosphorylation was inhibited at both residues by pretreatment with PP2 (5 µM, 30 min) (Fig. 5A). Immunoprecipitation of ghrelin-treated cells (100 nM, 10 min) with antibodies for β -arrestin 1 or β-arrestin 2 coprecipitated full-activated Akt showing an increase on tyrosine phosphorylation compared to untreated cells (Fig. 5B). Furthermore, the activated form of Src, pSrc (Y416), co-immunoprecipitated with β-arrestin 1 or β-arrestin 2 (Fig. 5B).
A, Effects of the Src inhibitor PP2 and its negative control, PP3, on the ghrelin-induced Akt activation in 3T3-L1 preadipocyte cells. Serum-starved cells were pretreated with PP2 (5 µM, 30 min) or PP3 (5 µM, 30 min) before ghrelin stimulation (100 nM) for the indicated time periods. Akt phosphorylation was quantified by densitometry and expressed as a percentage of the maximal phosphorylation at HM (S473) and A-loop (T308) (mean±S.E of three independent experiments). B, Effect of ghrelin on the assembly of complexes containing β-arrestins 1 and 2 and pAkt. Preadipocyte 3T3-L1 cells were incubated with ghrelin (100 nM, 10 min) at 37°C, lysed and immunoprecipitated (IP) with antibodies to β-arrestins 1 and 2, and then analyzed by western blotting with pAkt HM (S473), pAkt A-loop (T308), pY, pSrc (Y416) antibodies. For A and B, western blots are representative of three independent experiments.
The present study offers three major findings related to the activation of Akt in response to ghrelin. First, Akt is phosphorylated by the interplay of two Gi/o-protein-dependent signaling pathways. One pathway is Gβγ-dependent and involves the activation of PI3K. The second pathway is mediated by the β-arrestins 1 and 2, and requires the entry of the receptor into a multiprotein complex. Second, PDK1 and mTORC2 are essential for A-loop and HM phosphorylation of Akt, respectively. Third, c-Src plays an essential role in the activation of Akt mediated by ghrelin. Thus, ghrelin activates Akt pools that differ in their temporal and spatial distributions, suggesting to have different physiological targets.
The protein kinase Akt has emerged as a pivotal signaling node that regulates the control of cell proliferation, nutrient uptake and metabolism in a cell-type-specific manner through a variety of down-stream targets . From the results presented so far, ghrelin activates Akt by two distinct phosphorylation events, both of which depend on PI3K. GHS-R1a activates PI3K through Gi/o protein to regulate several downstream signaling pathways through the generation of the lipid second messenger phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3] . Since expression of Gβγ sequestrant inhibited both Akt HM (S473) and A-loop (T308) phosphorylation, we suggest that Gβγ dimers from Gi/o are the upstream signal for PI3K activation . PtdIns(3,4,5)P3 allows membrane translocation of proteins containing PH domain such as PDK1 and Akt. Then, PDK1 is autophosphorylated at Ser241 leading to its own activation and consequently phosphorylates Akt A-loop (T308) , . Finally, the full activation of Akt involves the phosphorylation of HM (S473). Several kinases, designated as PDK2 kinases, have been proposed to phosphorylate the Akt HM (S473) kinase; from those at least 10 of them may function as PDK2, including integrin-linked kinase (ILK), protein kinase Cα (PKCα), double-stranded DNA-dependent protein kinase (DNA-PK), ataxia telangengiectasia mutated (ATM) gene product, and the mTORC2 . From all the proposed candidates, evidence supports mTORC2 as the most compelling. mTORC2 contains Rictor, mLST8, mSin1 variants and the mTOR kinase . Our study shows that ablating mTORC2 function by siRNA targeting Rictor impaired ghrelin-stimulated HM (S473) phosphorylation of Akt, but not at the A-loop (T308). This result identifies the hypothetical ghrelin-activated PDK2 as mTORC2. The fact that the Akt A-loop (T308) phosphorylation is unaffected by loss of HM (S473) phosphorylation in mTORC2-deficient cells, supports that the phosphorylation of HM (S473) is not critical for that of A-loop (T308). Thus, the PDK1-mediated Akt A-loop (T308) phosphorylation is not dependent on prior HM (S473) phosphorylation by mTORC2 –. Interestingly, PTX treatment selectively enhanced earliest time points of Akt HM (S473) phosphorylation, consistent with a regulatory role of Gαi/o protein. This opens the possibility that Gαi/o regulates the activation of the recently discovered PH domain leucine-rich repeat phosphatase (PHLPP1 and PHLPP2), phosphatases that selectively dephosphorylate the HM of Akt, resulting in decreased kinase activity , . These results support the model by which both Akt and PDK1 interact by colocalization at the plasma membrane, which is further phosphorylated by mTORC2 . Despite being a key element in the Akt activation, the way mTORC2 is activated remains unknown. Based on the PH-like domain of mSIN1, mTORC2 and Akt might interact as consequence of colocalization at plasma membrane when PI3K is activated . This does not exclude the possibility that other upstream signals regulate phosphorylation/activation of the mTORC2 in response to different growth factors. Indeed mSIN1 contains a Ras-binding domain raising the possibility that Ras regulates mTORC2 , .
c-Src kinase is involved in the MAPK activation in response to ghrelin. Ghrelin induces a first “wave” of c-Src activation via G protein-dependent signaling that it is followed by a second wave of c-Src activation via β-arrestins-mediated signaling . In the present work, c-Src acts upstream of Akt, as c-Src depletion using siRNAs reduced the ghrelin-induced Akt phosphorylation at both A-loop (T308) and HM (S473). It was reported that, in addition to phosphorylation of A-loop (T308) and HM (S473), Y phosphorylation is also essential for Akt activation , . Our data indicate that ghrelin activates Y phosphorylation of Akt, although the detailed mechanism of this regulation remains to be elucidated. Additionally, coimmunoprecipitation assays showed that c-Src interacts with Akt in response to ghrelin. Because c-Src contains an SH3 domain, it was proposed that Src interacts with the PXXP motif of Akt . Our data are consistent with this previously proposed model in which Akt translocates to the plasma membrane through the binding of its PH domain to PtdIns(3,4,5)P3 generated by PI3K. This allows the interaction of membrane bound Src and Akt through its PXXP motif in the C-terminal regulatory region and the SH3 domain of Src. Then Src phosphorylates Akt at Y residue(s), which triggers Akt A-loop (T308) and HM (S473) phosphorylation by PDK1 and mTORC2 . These data support the idea that Src operates as a “switch” in concert with PI3K for activation of Akt in response to ghrelin.
The existence of a pathway involving receptor endocytosis is supported by the fact that β-arrestin depletion using siRNAs reduced the magnitude of Akt activation by ghrelin. Our coimmunoprecipitation assays indicate that the β-arrestins function as adaptors recruiting Akt to the ghrelin-occupied receptor through the formation of β-arrestin complexes. The mechanism of activation of Akt-associated to β-arrestins is not completely delineated. From the data presented so far, c-Src is essential for Akt activation even when is associated to β-arrestins. Given that c-Src is recruited to GHS-R1a upon ghrelin stimulation , it would be possible that Akt interacts with Src associated to GHSR1a-β-arrestin complex as consequence of colocalization at plasma membrane when PI3K is activated in response to ghrelin. This Akt-c-Src association is presumed to initiate Akt phosphorylation by allowing Y phosphorylation. Furthermore, β-arrestin-scaffolded complex presumably places the different components of the Akt cascade in close proximity to each other and thus ensuring substrate specificity. This is supported by the fact that neither PDK1 nor mTORC2 coimmunoprecipitated with β-arrestins. Interestingly, both β-arrestin 1 and β-arrestin 2 are required to promote the activation of Akt. The requirement of both proteins might be indicative of a need to form heterodimers to activate the β-arrestin-dependent signaling pathway as it was described for MAPK activation . However, this cannot be generalized, since in other systems β-arrestins show opposite effects. For example, in the case of the D2-class receptors, β-arrestin 2 facilitates the dephosphorylation of Akt by phosphatase 2 (PP2A) in response to dopamine , . In addition, prostaglandin E2 , IGF-1 , α-thrombin  and β1-adrenergic receptors ,  activate Akt pathway through β-arrestin 1 dependent mechanisms. It seems that each receptor determine the β-arrestin-associated functions on basis of the receptor-associated isoforms.
It has been shown that ghrelin regulates the Akt activity through the GHS-R1a in a variety of cellular systems –. Particularly, the mitogenic effect of ghrelin in 3T3-L1 preadipocytes is mediated by the PI3K/Akt and MAPK pathways, via a Gi-protein . Accordingly to our results in HEK-GHSR1a cells, co-immunoprecipitation assays performed in 3T3-L1 cells indicate that β-arrestins recruit Akt, leading to its activation. c-Src acts upstream of Akt in these cells, as PP2 abolished the ghrelin-induced Akt phosphorylation at both residues. Furthermore, co-immunoprecipitation assays showed that c-Src interacts with Akt in response to ghrelin allowing the phosphorylation of Akt at Y residue(s). Therefore, our data are consistent with a model in which Akt translocates to the plasma membrane through the binding of its PH domain to the second messenger PtdIns(3,4,5)P3 generated by PI3K which is activated through Gi/o-protein dependent signaling pathway. Akt is phosphorylated at Y by the membrane bound Src via the interaction between its C-terminal proline-rich motif and the SH3 domain of Src. This Y phosphorylation is followed by phosphorylation of Akt A-loop (T308) and HM (S473) by PDK1 and mTORC2 respectively. Once the receptor is activated, a second signaling pathway is mediated by β-arrestins 1 and 2 involving the recruitment of GHS-R1a, c-Src and Akt into an β-arrestin-scaffolded complex (Fig. 6). Thus c-Src functions as a switch that initiates the Akt pathway associated to both the Gi/o-protein dependent pathway and β-arrestin-scaffolded complex.
Binding of ghrelin to GHS-R1a activates the generation of the second messenger PtdIns(3,4,5)P3 (PIP3) by PI3K activation through Gi/o-protein dependent signaling pathway. Akt translocates to the plasma membrane by binding to PIP3 where it is phosphorylated at Y by the membrane bound c-Src. This phosphorylation (Y) is followed by phosphorylation of Akt A-loop (T308) and HM (S473) by PDK1 and mTORC2 respectively. Once the receptor is activated, a second signaling pathway is mediated by β-arrestins 1 and 2, involving the recruitment of GHS-R1a, c-Src and Akt into an β-arrestin-scaffolded complex.
We thank Prof. R.J. Lefkowitz for antibody against β-arrestins (Howard Hughes Medical Institute and the Departments of Medicine and Biochemistry, Duke University Medical Center).
Conceived and designed the experiments: JPC. Performed the experiments: ML. Analyzed the data: ML MT FFC JPC. Contributed reagents/materials/analysis tools: MT MP. Wrote the paper: JPC.
- 1. van der Lely AJ, Tschop M, Heiman ML, Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426–457.
- 2. Camiña JP, Carreira MC, El Messari S, Llorens-Cortes C, Smith RG, et al. (2004) Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a. Endocrinology 145: 930–940.
- 3. Holliday ND, Holst B, Rodionova EA, Schwartz TW, Cox HM (2007) Importance of constitutive activity and arrestin-independent mechanisms for intracellular trafficking of the ghrelin receptor. Mol Endocrinol 21: 3100–12.
- 4. Luttrell LM, Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115: 455–465.
- 5. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483–510.
- 6. Camiña JP, Lodeiro M, Ischenko O, Martini AC, Casanueva FF (2007) Stimulation by ghrelin of p42/p44 mitogen-activated protein kinase through the GHS-R1a receptor: role of G-proteins and beta-arrestins. J Cell Physiol 213: 187–200.
- 7. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261–1274.
- 8. Xu X, Jhun BS, Ha CH, Jin ZG (2008) Molecular Mechanisms of Ghrelin-Mediated Endothelial Nitric Oxide Synthase Activation. Endocrinology. In press.
- 9. Iantorno M, Chen H, Kim JA, Tesauro M, Lauro D, et al. (2007) Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292: E756–64.
- 10. Rossi F, Bertone C, Petricca S, Santiemma V (2007) Ghrelin inhibits angiotensin II-induced migration of human aortic endothelial cells. Atherosclerosis 192: 291–297.
- 11. Zhao H, Liu G, Wang Q, Ding L, Cai H, et al. (2007) Effect of ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun 362: 677–681.
- 12. Barazzoni R, Zanetti M, Cattin MR, Visintin L, Vinci P, et al. (2007) Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats. Obesity (Silver Spring) 15: 2614–2623.
- 13. Park YJ, Lee YJ, Kim SH, Joung DS, Kim BJ, et al. (2008) Ghrelin enhances the proliferating effect of thyroid stimulating hormone in FRTL-5 thyroid cells. Mol Cell Endocrinol 285: 19–25.
- 14. Kim MS, Yoon CY, Jang PG, Park YJ, Shin CS, et al. (2004) The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. Mol Endocrinol 18: 2291–22301.
- 15. Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, et al. (2003) Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun 309: 464–468.
- 16. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, et al. (2006) Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66: 1576–1582.
- 17. Schwindinger WF, Robishaw JD (2001) Heterotrimeric G-protein betagamma-dimers in growth and differentiation. Oncogene 20: 1653–1660.
- 18. Casamayor A, Morrice NA, Alessi DR (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342: 287–292.
- 19. Storz P, Toker A (2002) 3′-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 7: 886–902.
- 20. Dong LQ, Liu F (2005) PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 289: E187–196.
- 21. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9–22.
- 22. Biondi RM, Kieloch A, Currie RA, Deak M, Alessi DR (2001) The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 20: 4380–4390.
- 23. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859–871.
- 24. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125–137.
- 25. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11: 583–589.
- 26. Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13–24.
- 27. Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917–931.
- 28. Schroder WA, Buck M, Cloonan N, Hancock JF, Suhrbier A, et al. (2007) Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. Cell Signal 19: 1279–1289.
- 29. Lee S, Comer FI, Sasaki A, McLeod IX, Duong Y, et al. (2005) TOR complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium. Mol Biol Cell 2005 16: 4572–4583.
- 30. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, et al. (2001) Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 276: 31858–31862.
- 31. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB (2002) Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem 277: 38021–38028.
- 32. Jiang T, Qiu Y (2003) Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278: 15789–15793.
- 33. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, et al. (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125–136.
- 34. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, et al. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261–273.
- 35. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, et al. (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 103: 1492–1497.
- 36. Povsic TJ, Kohout TA, Lefkowitz RJ (2003) Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278: 51334–51339.
- 37. Goel R, Phillips-Mason PJ, Raben DM, Baldassare JJ (2002) alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression. J Biol Chem 277: 18640–18648.
- 38. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, et al. (2007) Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117: 2445–2458.
- 39. Morisco C, Marrone C, Galeotti J, Shao D, Vatner DE, et al. (2008) Endocytosis machinery is required for beta1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes. Cardiovasc Res 78: 36–44.